---
figid: PMC9266842__ijms-23-07353-g002
figtitle: Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition
  Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast
  Cancer
organisms:
- NA
pmcid: PMC9266842
filename: ijms-23-07353-g002.jpg
figlink: /pmc/articles/PMC9266842/figure/ijms-23-07353-f002/
number: F2
caption: The overview of PI3K/AKT/mTOR, RAS-RAF-MEK-ERK, and MEK5/ERK5 pathway, with
  their respective small molecule inhibitors. The immune-modulatory effect of both
  PI3K and MAPK inhibition provides a promising option to overcome therapeutic resistance
  with ICIs. Dual-targeted inhibition of MAPK and PI3K pathway effectors in combination
  or with sequential treatment with ICIs may present a potential strategy to overcome
  resistance in patients with tumors harboring both pathway-associated mutations.
  FDA-approved therapeutic agents are denoted in red. Inhibitors with an asterisk
  (*) are approved in melanoma. Created with BioRender.com.
papertitle: Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition
  Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast
  Cancer.
reftext: Zhizhu Zhang, et al. Int J Mol Sci. 2022 Jul;23(13):7353.
year: '2022'
doi: 10.3390/ijms23137353
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: melanoma | triple-negative breast cancer | PI3K/AKT/mTOR | MAPK/MEK/ERK
  | immune checkpoint blockade
automl_pathway: 0.9485837
figid_alias: PMC9266842__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC9266842__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9266842__ijms-23-07353-g002.html
  '@type': Dataset
  description: The overview of PI3K/AKT/mTOR, RAS-RAF-MEK-ERK, and MEK5/ERK5 pathway,
    with their respective small molecule inhibitors. The immune-modulatory effect
    of both PI3K and MAPK inhibition provides a promising option to overcome therapeutic
    resistance with ICIs. Dual-targeted inhibition of MAPK and PI3K pathway effectors
    in combination or with sequential treatment with ICIs may present a potential
    strategy to overcome resistance in patients with tumors harboring both pathway-associated
    mutations. FDA-approved therapeutic agents are denoted in red. Inhibitors with
    an asterisk (*) are approved in melanoma. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - pan
  - Panx
  - Mtor
  - Tor
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pdk1
  - Akt
  - Crtc
  - Pten
  - Skp2
  - Myb
  - Pi3K21B
  - Taf5
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - IRSp53
  - IleRS
  - chico
  - Pi3K59F
  - Pi3K68D
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - bi
  - rl
  - ADA2
  - PIK3CA
  - MTOR
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - RPTOR
  - PTEN
  - SKP2
  - UXT
  - MAPKAP1
  - RICTOR
  - MLST8
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - EGFR
  - IGF1R
  - ERBB2
  - KRAS
  - HRAS
  - NRAS
  - ARAF
  - RAF1
  - BRAF
  - MAPK3
  - MAPK1
  - MAP2K1
  - MAP3K2
  - MAP3K3
  - MAP2K5
  - MAPK7
---
